ClinicalTrials.gg
Not yet recruitingNCT07852949Updated Oct 1, 2026

Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans

An interventional study of Survey in Head and Neck Cancer and Prostate Cancer, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Device feasibility

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center — 8 open to participants now, 21 under way, 1 of them phase 3. Head and Neck Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
13th of 56
94 · median 25
Started
2027
with 1 other
No phase
17 of 74
4 open now
Primary completion
2027-12
later than 15 of 20 live
Registered
73rd of 74
by date

Among the 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center, this one is the 13th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2027, is one of 17 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 73rd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

8 of the 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The purpose of this research study is to learn if a digital communication tool can improve how well patients with head and neck cancer and their caregivers understand the disease and treatment plan after their first consultation visit with the doctor/nurse practitioner.

Read the detailed description

Primary Objective:

The primary objective of this pilot study is to determine whether use of a novel digital visual communication tool improves patient understanding and satisfaction with their initial multidisciplinary consultation for head and neck and prostate cancer. Specifically, the study seeks to answer the scientific question:

  • Do at least 75% of newly diagnosed head and neck and prostate cancer patients report being "satisfied" (≥4 positive responses on a 6-item survey) after use of the digital communication tool, and is this proportion significantly greater than 50%?

Secondary Objectives:

Caregiver Understanding and Satisfaction

  • What proportion of caregivers of newly diagnosed patients report satisfaction with their understanding of the patient's disease and treatment after using the tool, and how confident can we be in this estimate (95% Clopper-Pearson CI)?

Provider Experience and Communication Effectiveness

  • What proportion of providers report satisfaction (≥5 positive responses on a 7-item survey) with the tool's ability to improve communication efficiency and consultation quality for patients they treated?
03

Conditions studied

  • Head and Neck Cancer
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients

  • Adults aged 18 to 100 years.
  • Diagnosed with head and neck cancer (all histologies included).
  • Receiving treatment for head and neck and prostate cancer at MDACC
  • Able to speak and understand English

Caregivers

  • Adults (≥18 years old).
  • Identified as a caregiver to a patient who meets the above patient inclusion criteria.
  • Able to speak and understand English.

Providers

  • Doctors or nurse practitioners practicing in the field of radiation oncology and actively participating in initial consultations for patients with head and neck cancer and prostate cancer.
  • Must complete the provider survey after the consultation.

Exclusion criteria

Exclusion Criteria:

Patients

  • Individuals without a diagnosis of head and neck cancer or prostate cancer.
  • Patients who do not speak English (since the digital tool is not translated).

Caregivers

  • Adults who are not caregivers of the eligible patient
  • Caregivers who do not speak English (tool not translated).

Providers

  • Doctors or nurse practitioners not practicing in the field of radiation oncology and not part of the initial consultation process.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Patient/Caregiver: Use of MyCareGorithm

    Following use of the digital visual communication tool by the provider, patients and any accompanying caregivers will be asked to complete their surveys via REDCap. Providers will complete their survey immediately after the consultation with each participating patient, also via REDCap. Each survey requires approximately 5 minutes to complete. No follow-up surveys or repeat administrations are planned.

    Other: Survey

Interventions

  • OtherSurvey

    A 6-item structured questionnaire with Yes/No response options, followed by one open-ended free-text question.

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Dec 2027, 9 months later.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 9 months is below that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 1, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852949
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Steven J Frank, MD
Contact
sjfrank@mdanderson.org
(713) 563-3601
Steven J Frank, MD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion